Kronos Bio (NASDAQ:KRON - Get Free Report) is anticipated to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, May 8th. Analysts expect Kronos Bio to post earnings of ($0.30) per share for the quarter.
Kronos Bio (NASDAQ:KRON - Get Free Report) last posted its earnings results on Tuesday, March 18th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.13). Kronos Bio had a negative return on equity of 64.55% and a negative net margin of 867.66%. The business had revenue of $2.27 million for the quarter, compared to analyst estimates of $1.00 million. On average, analysts expect Kronos Bio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Kronos Bio Stock Performance
Shares of NASDAQ KRON traded down $0.01 during mid-day trading on Friday, reaching $0.71. 2,564,576 shares of the company's stock were exchanged, compared to its average volume of 283,054. The company's 50-day moving average is $0.87 and its 200-day moving average is $0.93. The firm has a market capitalization of $43.00 million, a price-to-earnings ratio of -0.49 and a beta of 1.78. Kronos Bio has a 52-week low of $0.67 and a 52-week high of $1.60.
Kronos Bio Company Profile
(
Get Free Report)
Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.
Read More
Before you consider Kronos Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kronos Bio wasn't on the list.
While Kronos Bio currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
